Intracellular mechanisms regulating corticotropin-releasing hormone receptor-2β endocytosis and interaction with extracellularly regulated kinase 1/2 and p38 mitogen-activated protein kinase signaling cascades

Molecular Endocrinology

Volumn 22, Issue 3, 2008, Pages 689-706

  Markovic, Danijela ^a   Punn, Anu ^a   Lehnert, Hendrik ^a   Grammatopoulos, Dimitris K ^a,b  

^a UNIVERSITY OF WARWICK   (United Kingdom)

^b UNIVERSITY OF WARWICK   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; CORTICOTROPIN RELEASING FACTOR 2 BETA; CORTICOTROPIN RELEASING FACTOR DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE P38; UNCLASSIFIED DRUG; UROCORTIN II;

ARTICLE; CELL MEMBRANE; CELL STRAIN HEK293; CONTROLLED STUDY; CYTOPLASM; ENDOCYTOSIS; ENZYME ACTIVATION; ENZYME LOCALIZATION; HORMONE ACTION; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN INTERACTION; SITE DIRECTED MUTAGENESIS;

AMINO ACID MOTIFS; ARRESTINS; CELL LINE; CLATHRIN; CORTICOTROPIN-RELEASING HORMONE; CYCLIC AMP; ENDOCYTOSIS; ENZYME ACTIVATION; HUMANS; MAP KINASE SIGNALING SYSTEM; MICROSCOPY, FLUORESCENCE; MITOGEN-ACTIVATED PROTEIN KINASES; MUTAGENESIS, SITE-DIRECTED; RECEPTORS, CORTICOTROPIN-RELEASING HORMONE; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, SMALL INTERFERING; TRANSFECTION; UROCORTINS;

EID: 40849120814     PISSN: 08888809     EISSN: None     Source Type: Journal    
DOI: 10.1210/me.2007-0136     Document Type: Article

References (34)

1. Bale TL, Vale WW 2004 CRF and CRF receptors: role in stress responsivity and other behaviors. Annu Rev Pharmacol Toxicol 244:525-557
2. Hillhouse EW, Grammatopoulos DK 2006 The molecular mechanisms underlying the regulation of the biological activity of corticotropin-releasing hormone receptors: implications for physiology and pathophysiology. Endocr Rev 27:260-286
3. Lewis K, Li C, Perrin MH, Blount A, Kunitake K, Donaldson C, Vaughan J, Reyes TM, Gulyas J, Fischer W, Bilezikjian L, Rivier J, Sawchenko PE, Vale WW 2001 Identification of urocortin III, an additional member of the corticotropin-releasing factor (CRF) family with high affinity for the CRF2 receptor. Proc Natl Acad Sci USA 98:7570-7575
4. Bale TL, Contarino A, Smith GW, Chan R, Gold LH, Sawchenko PE, Koob GF, Vale WW, Lee KF 2000 Mice deficient for corticotropin-releasing hormone receptor-2 display anxiety-like behaviour and are hypersensitive to stress. Nat Genet 24:410-414
5. Lawrence KM, Latchman DS 2006 The urocortins: mechanisms of cardioprotection and therapeutic potential. Mini Rev Med Chem 6:1119-1126
6. Bale TL, Giordano FJ, Hickey RP, Huang Y, Nath AK, Peterson KL, Vale WW, Lee KF 2002 Corticotropin-releasing factor receptor 2 is a tonic suppressor of vascularization. Proc Natl Acad Sci USA 99:7734-7739
7. Carlin KM, Vale WW, Bale TL 2006 Vital functions of corticotropin- releasing factor (CRF) pathways in maintenance and regulation of energy homeostasis. Proc Natl Acad Sci USA 103:3462-3467
8. Chen A, Brar B, Choi CS, Rousso D, Vaughan J, Kuperman Y, Kim SN, Donaldson C, Smith SM, Jamieson P, Li C, Nagy TR, Shulman GI, Lee KF, Vale W 2006 Urocortin 2 modulates glucose utilization and insulin sensitivity in skeletal muscle. Proc Natl Acad Sci USA 103:16580-16585
9. Li C, Chen P, Vaughan J, Blount A, Chen A, Jamieson PM, Rivier J, Smith MS, Vale W 2003 Urocortin III is expressed in pancreatic β-cells and stimulates insulin and glucagon secretion. Endocrinology 144:3216-3224
10. Hoare SR, Sullivan SK, Fan J, Khongsaly K, Grigoriadis DE 2005 Peptide ligand binding properties of the corticotropin-releasing factor (CRF) type 2 receptor: pharmacology of endogenously expressed receptors, G-protein-coupling sensitivity and determinants of CRF2 receptor selectivity. Peptides 26:457-470
11. Sananbenesi F, Fischer A, Schrick C, Spiess J, Radulovic J 2003 Mitogen-activated protein kinase signaling in the hippocampus and its modulation by corticotropin-releasing factor receptor 2: a possible link between stress and fear memory. J Neurosci 23:11436-11443
12. Karteris E, Hillhouse EW, Grammatopoulos D 2004 Urocortin II is expressed in human pregnant myometrial cells and regulates myosin light chain phosphorylation: potential role of the type-2 corticotropin-releasing hormone receptor in the control of myometrial contractility. Endocrinology 145:890-900
13. Dermitzaki E, Tsatsanis C, Gravanis A, Margioris AN 2002 Corticotropin-releasing hormone (CRH) induces Fas ligand production and apoptosis in PC12 cells via activation of p38 MAPK. J Biol Chem 277:12280-12287
14. Grammatopoulos D, Randeva H, Levine MA, Katsanou E, Hillhouse EW 2000 Urocortin but not corticotropin-releasing hormone (CRH) activates the MAP kinase signal transduction pathway in human pregnant myometrium: an effect mediated via R1α and R2β CRH receptor subtypes and stimulation of Gq-proteins. Mol Endocrinology 14:2076-2091
15. Brar BK, Chen A, Perrin MH, Vale W 2004 Specificity and regulation of extracellularly regulated kinase 1/2 phosphorylation through corticotropin-releasing factor (CRF) receptors 1 and 2β by the CRF/urocortin family of peptides. Endocrinology 145:1718-1729
16. Claing A, Laporte SA, Caron MG, Lefkowitz RJ 2002 Endocytosis of G protein-coupled receptors: roles of G protein-coupled receptor kinases and β-arrestin proteins. Prog Neurobiol 66:61-79
17. Lefkowitz RJ, Shenoy SK 2005 Transduction of receptor signals by β-arrestins. Science 308:512-517
18. Teli T, Markovic D, Levine MA, Hillhouse EW, Grammatopoulos D 2005 Regulation of corticotrophin releasing hormone (CRH) receptor type 1α signaling: structural determinants for G protein-coupled receptor kinase-mediated phosphorylation and agonist-mediated desensitization. Mol Endocrinol 19:474-490
19. Markovic D, Papadopoulou N, Teli T, Levine MA, Hillhouse EW, Grammatopoulos DK 2006 Differential responses of CRH receptor type 1 variants to PKC phosphorylation. J Pharmacol Exp Ther 19:1032-1042
20. Perry SJ, Junger S, Kohout TA, Hoare SR, Struthers RS, Grigoriadis DE, Maki RA 2005 Distinct conformations of the corticotropin releasing factor type 1 receptor adopted following agonist and antagonist binding are differentially regulated. J Biol Chem 280:11560-11568
21. Punn A, Levine MA, Grammatopoulos DK 2006 Identification of signaling molecules mediating CRH-R1α-MAPK interactions: the critical role of PI3-K in regulating ERK1/2 but not p38 MAPK activation. Mol Endocrinol 20:3179-3195
22. Miller JW 2004 Tracking G protein-coupled receptor trafficking using Odyssey Imaging. LI-COR Biosciences Application notes, pp 1-4 (http://www.licor.com/bio/PDF/Miller_GPCR.pdf)
23. Lin FT, Miller WE, Luttrell LM, Lefkowitz RJ 1999 Feedback regulation of β-arrestin1 function by extracellular signal-regulated kinases. J Biol Chem 274:15971-15974
24. Holmes KD, Babwah AV, Dale LB, Poulter MO, Ferguson SS 2006 Differential regulation of corticotropin releasing factor 1α receptor endocytosis and trafficking by β-arrestins and Rab GTPases. J Neurochem 96:934-949
25. Shenoy SK, Lefkowitz RJ 2003 Multifaceted roles of β-arrestins in the regulation of seven-membrane-spanning receptor trafficking and signalling. Biochem J 375:503-515
26. Oakley RH, Laporte SA, Holt JA, Barak LS, Caron MG 1999 Association of β-arrestin with G protein-coupled receptors during clathrin-mediated endocytosis dictates the profile of receptor resensitization. J Biol Chem 274:32248-32257
27. Kenakin T 1997 Agonist-specific receptor conformations. Trends Pharmacol Sci 18:232-238
28. Krupnick JG, Santini F, Gagnon AW, Keen JH, Benovic JL 1997 Modulation of the arrestin-clathrin interaction in cells. Characterization of β-arrestin dominant-negative mutants. J Biol Chem 272:32507-32512
29. Smith MP, Ayad VJ, Mundell SJ, McArdle CA, Kelly E, Lopez Bernal A 2005 Internalization and desensitization of the oxytocin receptor is inhibited by dynamin and clathrin mutants in human embryonic kidney 293 cells. Mol Endocrinol 20:379-388
30. Kageyama K, Hanada K, Suda T 2005 Regulation of corticotropin-releasing factor receptor type 2β mRNA by mitogen-activated protein kinases in aortic smooth muscle cells. Regul Pept 126:223-231
31. Luttrell DK, Luttrell LM 2003 Signaling in time and space: G protein-coupled receptors and mitogen-activated protein kinases. Assay Drug Dev Technol 1:327-338
32. Gesty-Palmer D, Chen M, Reiter E, Ahn S, Nelson CD, Wang S, Eckhardt AE, Cowan CL, Spurney RF, Luttrell LM, Lefkowitz RJ 2006 Distinct β-arrestin- and G protein-dependent pathways for parathyroid hormone receptor-stimulated ERK1/2 activation. J Biol Chem 281:10856-10864
33. McPherson G 1983 A practical computer based approach to the analysis of radioligand binding experiments. Prog Biomed 17:107-114
34. Munson P, Rodgbard D 1980 LIGAND: a versatile computerized approach for characterization of ligand binding systems. Anal Biochem 107:220-239